CCA
ABBV icon

Cypress Capital Advisors’s AbbVie ABBV Stock Holding History

Cypress Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Sell
5,872
-96
-2% -$21.3K 0.69% 22
2025
Q4 		$1.36M Sell
5,968
-34
-0.6% -$7.75K 0.73% 24
2025
Q3 		$1.39M Sell
6,002
-125
-2% -$25.5K 0.79% 22
2025
Q2 		$1.14M Sell
6,127
-36
-0.6% -$6.69K 0.71% 26
2025
Q1 		$1.29M Buy
6,163
+258
+4% +$50.2K 0.9% 20
2024
Q4 		$1.05M Buy
+5,905
New +$1.09M 0.82% 23

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cypress Capital Advisors's ABBV Position: Q1 2026 in Review

Cypress Capital Advisors reduced its AbbVie (ABBV) stake by 1.6% in Q1 2026, selling an estimated $21.3K and leaving 5,872 shares worth $1.28M. The position accounts for 0.69% of the portfolio, ranked #22.

Cypress Capital Advisors first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.39M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cypress Capital Advisors held 5,872 shares of AbbVie worth $1.28M as of Q1 2026.
  • Cypress Capital Advisors sold 96 AbbVie shares in Q1 2026, an estimated $21.3K.
  • AbbVie made up 0.69% of Cypress Capital Advisors's portfolio in Q1 2026, its #22 holding.
  • Cypress Capital Advisors first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • Cypress Capital Advisors's AbbVie position peaked at $1.39M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cypress Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.